Modeling breast cancer by grafting patient tumor samples in the avian embryo: an in vivo platform for therapy evaluation coupled to large scale molecular analyses
Jarrosson, L.; Costechareyre, C.; Gallix, F.; Cire, S.; Gay, F.; Imbaud, O.; Marangoni, E.; Aguera, K.; Delloye-Bourgeois, C.; Castellani, V.
Show abstract
Lack of preclinical patient-derived xenograft (PDX) cancer models in which to conduct large scale molecular studies seriously impairs the development of effective personalized therapies. We report here on an in vivo concept consisting of implanting human tumor cells in targeted tissues of an avian embryo, delivering therapeutics, evaluating their efficacy by measuring tumors using light sheet confocal microscopy, and conducting large scale RNAseq analysis to characterize therapeutic-induced changes in gene expression. The model was established to recapitulate triple negative breast cancer (TNBC) and validated using TNBC standards of care (SOCs) and an investigational therapeutic agent.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Selective refueling of CAR T cells using ADA1 and 1 CD26 boosts antitumor immunity 93%
- Genome profiles of lymphovascular breast cancer cells reveal multiple clonally differentiated outcomes with multi-regional LCM and G&T-seq 92%
- Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors 92%
Similar papers in this journal
- Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer 93%
- Tumor expressed CD95 causes suppression of anti-tumor activity of NK cells in a model of triple negative breast cancer 93%
- Versatile roles of Annexin A4 in ccRCC: impact on membrane repair, transcriptional signatures, and composition of the tumor microenvironment 92%
Similar papers in this journal
- Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth 93%
- ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 93%
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.